Psychedelic treatments show promise for treating PTSD and depression

The Royal Devon University Healthcare NHS Foundation Trust is leading ground-breaking clinical research that has the potential to transform treatments for neuropsychiatric disorders.

Duchenne muscular dystrophy drug flunks Phase 3 confirmatory trial

NS Pharma’s Duchenne muscular dystrophy drug Viltepso failed its confirmatory study. Despite the failure, the company is keeping faith in the drug and running further

May 29, 2024

Amgen secures full FDA approval for leukaemia therapy Blincyto – Pharmaceutical Technology

Amgen believes Blincyto, first granted accelerated approval in 2018, has been reinforced as standard of care. Credit: Shutterstock / Chalie Chulapornsiri. Based on a trial

June 22, 2023

Viagra and Alzheimer’s; Migraine Consensus Statement; FDA Updates Drug Guidance

More data supported links between the erectile dysfunction drug sildenafil (Viagra) and reduced Alzheimer’s risk. (Journal of Alzheimer’s Disease) The American Headache Society issued a

March 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.